Strategic growth US BioTek Laboratories has recently expanded its diagnostic portfolio through the acquisition of RealTime Laboratories, signaling potential for cross-sell of related testing services and integrated lab solutions to new and existing healthcare clients.

Rapid results With a 24-hour turnaround for monkeypox testing and automated ELISA platforms, there is an opportunity to target urgent-care networks, hospitals, and clinics requiring fast, reliable immunoassay and infectious disease testing capabilities.

Broad capabilities The lab offers immunology, chemistry, metabolic, and pollutant profiling, plus at-home and finger-stick specimen options, which can be positioned to partners seeking comprehensive exposure, environmental, and personalized medicine testing in a single vendor relationship.

Global reach CLIA and CAP accreditation, 30+ years of ELISA expertise, and worldwide clinician coverage present a compelling case to pursue enterprise accounts, healthcare systems, and managed care organizations needing scalable, compliant laboratory services.

Growth financing Historical funding activity and leadership changes, including acquisition by Pike Street Capital and leadership appointments, suggest an active growth trajectory that could be leveraged to propose expanded service lines, contract manufacturing collaborations, or joint ventures with strategic investors.